15. Takamoto T, Hashimoto T, Sano K, et al. Recovery of liver function after the cessation of

preoperative chemotherapy for colorectal liver metastasis. Ann Surg Oncol 2010;17:2747–2755.

16. Kiriyama S, Uchiyama K, Ueno M, et al. Triple positive tumor markers for hepatocellular carcinoma

are useful predictors of poor survival. Ann Surg 2011;254:984–991.

17. Shindoh J, Sugawara Y, Nagata R, et al. Evaluation methods for pretransplant oncologic markers

and their prognostic impacts in patient undergoing living donor liver transplantation for

hepatocellular carcinoma. Transpl Int 2014;27:391–398.

1568

18. Fujiki M, Takada Y, Ogura Y, et al. Significance of des-gamma-carboxy prothrombin in selection

criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant

2009;9:2362–2371.

19. Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for

hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010;10:129–137.

20. Bruix J, Sherman M; Practice Guidelines Committee AAftSoLD. Management of hepatocellular

carcinoma. Hepatology 2005;42:1208–1236.

21. Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver

transplantation. N Engl J Med 2007;356:1545–1559.

22. Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted

therapy. Oncology 2008;75(suppl 1):1–12.

23. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage

liver disease. Hepatology 2001;33:464–470.

24. Cejas NG, Villamil FG, Lendoire JC, et al. Improved waiting-list outcomes in Argentina after the

adoption of a model for end-stage liver disease-based liver allocation policy. Liver Transpl

2013;19:711–720.

25. Schroeder RA, Marroquin CE, Bute BP, et al. Predictive indices of morbidity and mortality after

liver resection. Ann Surg 2006;243:373–379.

26. Teh SH, Christein J, Donohue J, et al. Hepatic resection of hepatocellular carcinoma in patients

with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J

Gastrointest Surg 2005;9:1207–1215; discussion 1215.

27. Nachmany I, Dvorchik I, Devera M, et al. A validated model for predicting outcome after liver

transplantation: implications on transplanting the extremely sick. Transpl Int 2013;26:1108–1115.

28. Agopian VG, Petrowsky H, Kaldas FM, et al. The evolution of liver transplantation during 3

decades: analysis of 5347 consecutive liver transplants at a single center. Ann Surg 2013;258:409–

421.

29. Koh DM, Collins DJ, Wallace T, et al. Combining diffusion-weighted MRI with Gd-EOB-DTPAenhanced MRI improves the detection of colorectal liver metastases. Br J Radiol 2012;85:980–989.

30. Arita J, Takahashi M, Hata S, et al. Usefulness of contrast-enhanced intraoperative ultrasound using

Sonazoid in patients with hepatocellular carcinoma. Ann Surg 2011;254:992–999.

31. Itabashi T, Sasaki A, Otsuka K, et al. Potential value of sonazoid-enhanced intraoperative

laparoscopic ultrasonography for liver assessment during laparoscopy-assisted colectomy. Surg

Today 2014;44:696–701.

32. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR

imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients

who have not previously undergone treatment. Radiology 2010;257:674–684.

33. Chen LB, Tong JL, Song HZ, et al. (18)F-DG PET/CT in detection of recurrence and metastasis of

colorectal cancer. World J Gastroenterol 2007;13:5025–5029.

34. Truant S, Huglo D, Hebbar M, et al. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-Dglucose positron emission tomography of resectable colorectal liver metastases. Br J Surg

2005;92:362–369.

35. Couinaud C. Surgical Anatomy of the Liver Revised. Paris, France: Couinaud; 1989.

36. Shindoh J, Mise Y, Satou S, et al. The intersegmental plane of the liver is not always flat–tricks for

anatomical liver resection. Ann Surg 2010;251:917–922.

37. Gamblin TC, Holloway SE, Heckman JT, et al. Laparoscopic resection of benign hepatic cysts: a

new standard. J Am Coll Surg 2008;207:731–736.

38. Vauthey JN, Maddern GJ, Blumgart LH. Adult polycystic disease of the liver. Br J Surg

1991;78:524–527.

39. Baber JT, Hiatt JR, Busuttil RW, et al. A 20-year experience with liver transplantation for

polycystic liver disease: does previous palliative surgical intervention affect outcomes? J Am Coll

Surg 2014;219(4):695–703.

40. Del Poggio P, Buonocore M. Cystic tumors of the liver: a practical approach. World J Gastroenterol

2008;14:3616–3620.

41. Devaney K, Goodman ZD, Ishak KG. Hepatobiliary cystadenoma and cystadenocarcinoma. A light

1569

microscopic and immunohistochemical study of 70 patients. Am J Surg Pathol 1994;18:1078–1091.

42. Wheeler DA, Edmondson HA. Cystadenoma with mesenchymal stroma (CMS) in the liver and bile

ducts. A clinicopathologic study of 17 cases, 4 with malignant change. Cancer 1985;56:1434–1445.

43. Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol

2005;39:401–412.

44. Gandolfi L, Leo P, Solmi L, et al. Natural history of hepatic haemangiomas: clinical and ultrasound

study. Gut 1991;32:677–680.

45. Mergo PJ, Ros PR. Benign lesions of the liver. Radiol Clin North Am 1998;36:319–331.

46. Terriff BA, Gibney RG, Scudamore CH. Fatality from fine-needle aspiration biopsy of a hepatic

hemangioma. AJR Am J Roentgenol 1990;154:203–204.

47. Erdogan D, Busch OR, van Delden OM, et al. Management of liver hemangiomas according to size

and symptoms. J Gastroenterol Hepatol 2007;22:1953–1958.

48. Miura JT, Amini A, Schmocker R, et al. Surgical management of hepatic hemangiomas: a multiinstitutional experience. HPB (Oxford) 2014;16(10):924–928.

49. Ozden I, Emre A, Alper A, et al. Long-term results of surgery for liver hemangiomas. Arch Surg

2000;135:978–981.

50. Corigliano N, Mercantini P, Amodio PM, et al. Hemoperitoneum from a spontaneous rupture of a

giant hemangioma of the liver: report of a case. Surg Today 2003;33:459–463.

51. Mungovan JA, Cronan JJ, Vacarro J. Hepatic cavernous hemangiomas: lack of enlargement over

time. Radiology 1994;191:111–113.

52. Karhunen PJ. Benign hepatic tumours and tumour like conditions in men. J Clin Pathol

1986;39:183–188.

53. Greaves WO, Bhattacharya B. Hepatic adenomatosis. Arch Pathol Lab Med 2008;132:1951–1955.

54. Grazioli L, Federle MP, Brancatelli G, et al. Hepatic adenomas: imaging and pathologic findings.

Radiographics 2001;21:877–892; discussion 892–874.

55. Shanbhogue A, Shah SN, Zaheer A, et al. Hepatocellular adenomas: current update on genetics,

taxonomy, and management. J Comput Assist Tomogr 2011;35:159–166.

56. Laumonier H, Bioulac-Sage P, Laurent C, et al. Hepatocellular adenomas: magnetic resonance

imaging features as a function of molecular pathological classification. Hepatology 2008;48:808–

818.

57. Farges O, Dokmak S. Malignant transformation of liver adenoma: an analysis of the literature. Dig

Surg 2010;27:32–38.

58. Stoot JH, Coelen RJ, De Jong MC, et al. Malignant transformation of hepatocellular adenomas into

hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB

(Oxford) 2010;12:509–522.

59. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular

adenoma: new classification and relationship with HCC. Hepatology 2006;43:515–524.

60. Farges O, Ferreira N, Dokmak S, et al. Changing trends in malignant transformation of

hepatocellular adenoma. Gut 2011;60:85–89.

61. van der Windt DJ, Kok NF, Hussain SM, et al. Case-orientated approach to the management of

hepatocellular adenoma. Br J Surg 2006;93:1495–1502.

62. Charny CK, Jarnagin WR, Schwartz LH, et al. Management of 155 patients with benign liver

tumours. Br J Surg 2001;88:808–813.

63. Gordon SC, Reddy KR, Livingstone AS, et al. Resolution of a contraceptive-steroid-induced hepatic

adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 1986;105:547–

549.

64. van Aalten SM, Witjes CD, de Man RA, et al. Can a decision-making model be justified in the

management of hepatocellular adenoma? Liver Int 2012;32:28–37.

65. Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122 patients with

single and multiple hepatocellular adenomas. Gastroenterology 2009;137:1698–1705.

66. Deneve JL, Pawlik TM, Cunningham S, et al. Liver cell adenoma: a multicenter analysis of risk

factors for rupture and malignancy. Ann Surg Oncol 2009;16:640–648.

67. Chun YS, House MG, Kaur H, et al. SSAT/AHPBA joint symposium on evaluation and treatment of

1570

benign liver lesions. J Gastrointest Surg 2013;17:636–644.

68. World Health Organization. World Cancer Report 2014. Lyon, France: The International Agency for

Research on Cancer; 2014.

69. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of

hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817–823.

70. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.

71. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: ConsensusBased Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010

updated version. Dig Dis 2011;29:339–364.

72. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular

carcinoma. J Cancer Res Clin Oncol 2004;130:417–422.

73. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis

and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251–259.

74. Tanaka H, Nouso K, Kobashi H, et al. Surveillance of hepatocellular carcinoma in patients with

hepatitis C virus infection may improve patient survival. Liver Int 2006;26:543–551.

75. Trevisani F, Cantarini MC, Labate AM, et al. Surveillance for hepatocellular carcinoma in elderly

Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol

2004;99:1470–1476.

76. Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance

for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010;53:291–

297.

77. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small

hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699.

78. Marrero JA, Hussain HK, Nghiem HV, et al. Improving the prediction of hepatocellular carcinoma

in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005;11:281–289.

79. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Semin Liver Dis 1999;19:329–338.

80. Lim C, Mise Y, Sakamoto Y, et al. Above 5 cm, size does not matter anymore in patients with

hepatocellular carcinoma. World J Surg 2014;38(11):2910–2918.

81. Shindoh J, Andreou A, Aloia TA, et al. Microvascular invasion does not predict long-term survival

in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann

Surg Oncol 2013;20:1223–1229.

82. Makuuchi M, Kosuge T, Takayama T, et al. Surgery for small liver cancers. Semin Surg Oncol

1993;9:298–304.

83. Hasegawa K, Kokudo N, Imamura H, et al. Prognostic impact of anatomic resection for

hepatocellular carcinoma. Ann Surg 2005;242:252–259.

84. Shindoh J, Hasegawa K, Inoue Y, et al. Risk factors of post-operative recurrence and adequate

surgical approach to improve long-term outcomes of hepatocellular carcinoma. HPB (Oxford)

2013;15:31–39.

85. Eguchi S, Kanematsu T, Arii S, et al. Comparison of the outcomes between an anatomical

subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas

based on a Japanese nationwide survey. Surgery 2008;143:469–475.

86. DuBay D, Sandroussi C, Sandhu L, et al. Liver transplantation for advanced hepatocellular

carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg

2011;253:166–172.

87. Herrero JI, Sangro B, Pardo F, et al. Liver transplantation in patients with hepatocellular carcinoma

across Milan criteria. Liver Transpl 2008;14:272–278.

88. Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular

carcinoma in living donor liver transplantation. Liver Transpl 2007;13:1637–1644.

89. Jonas S, Mittler J, Pascher A, et al. Living donor liver transplantation of the right lobe for

hepatocellular carcinoma in cirrhosis in a European center. Liver Transpl 2007;13:896–903.

90. Kwon CH, Kim DJ, Han YS, et al. HCC in living donor liver transplantation: can we expand the

Milan criteria? Dig Dis 2007;25:313–319.

1571

91. Lee SG, Hwang S, Moon DB, et al. Expanded indication criteria of living donor liver transplantation

for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008;14:935–945.

92. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients

with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.

Lancet Oncol 2009;10:35–43.

93. Silva M, Moya A, Berenguer M, et al. Expanded criteria for liver transplantation in patients with

cirrhosis and hepatocellular carcinoma. Liver Transpl 2008;14:1449–1460.

94. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular

carcinoma: Tokyo University series. Dig Dis 2007;25:310–312.

95. Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver

transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008;14:1107–1115.

96. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of

the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–1403.

97. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou

experiences. Transplantation 2008;85:1726–1732.

98. Kaczynski J, Hansson G, Wallerstedt S. Incidence, etiologic aspects and clinicopathologic features in

intrahepatic cholangiocellular carcinoma–a study of 51 cases from a low-endemicity area. Acta

Oncol 1998;37:77–83.

99. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the

United States: a true increase? J Hepatol 2004; 40:472–477.

100. Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and prognosis for patients with

intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg

2014;149(6):565–574.

101. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma.

Oncogene 2006;25:3818–3822.

102. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international

multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol

2011;29:3140–3145.

103. Almersjo O, Bengmark S, Hafstrom L. Liver metastases found by follow-up of patients operated on

for colorectal cancer. Cancer 1976;37:1454–1457.

104. Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the

liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by

laparotomy. Cancer 1969;23:198–202.

105. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg

2007;11:1057–1077.

106. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol

1997;15:938–946.

107. Ito H, Are C, Gonen M, et al. Effect of postoperative morbidity on long-term survival after hepatic

resection for metastatic colorectal cancer. Ann Surg 2008;247:994–1002.

108. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of

recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241:715–722, discussion

722–714.

109. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is

associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol

2009;27:3677–3683.

110. Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet

2008;371:963–965.

111. Chua TC, Saxena A, Liauw W, et al. Hepatectomy and resection of concomitant extrahepatic disease

for colorectal liver metastases–a systematic review. Eur J Cancer 2012;48:1757–1765.